Fig. 3

Rab27a knockdown disrupts secretion of EVs and suppresses the tumorigenicity and metastasis of GC NSCCs in vivo. A Rab27a expression in HGC-27 cells treated with sh-Rab27a-1 or sh-sh-Rab27a-2 measured by Western blot and RT-qPCR. B NTA of the number of EVs released by HGC-27 cells treated with sh-Rab27a. C Western blots and quantification analysis of EV positive marker proteins CD81, CD9, and Alix in HGC-27 cells treated with sh-Rab27a (the remaining protein expression in response to decreased expression of CD81, CD9 and Alix in the presence of sh-Rab27a was calculated with sh-NC as the reference). D Representative images showing tumors in mice and tumor weight of mice treated with sh-Rab27a or Nexinhib20. E Representative images of liver tissues and the quantitative analysis of liver metastases in mice treated with sh-Rab27a or Nexinhib20. F H&E staining of tumor tissues and liver tissues of mice treated with sh-Rab27a or Nexinhib20. The tumor tissue is in the dotted box. G Positive expression of Rab27a protein in tumor tissues of mice treated with sh-Rab27a or Nexinhib20 detected by immunohistochemistry. Cell experiments were conducted three times independently. n = 8 mice for each treatment. *p < 0.05, **p < 0.01